Complications of needle electromyography: Hematoma risk and correlation with anticoagulation and antiplatelet therapy

Stacy L. Lynch, Andrea Boon, Jay Smith, Charles M. Harper, Elisa M. Tanaka

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Electromyography (EMG) is considered a relatively safe procedure based primarily on clinical experience. Literature review reveals few reported complications from bleeding or hematoma formation. No evidence-based guidelines exist for EMG procedures in patients who are taking anticoagulant or antiplatelet medications. The purpose of this study was to determine if patients taking anticoagulant or antiplatelet agents exhibit an increased risk of hematoma formation after routine needle EMG of the tibialis anterior muscle when compared to controls. Study subjects underwent routine needle EMG of the tibialis anterior muscle followed by ultrasound examination to evaluate for the presence of hematoma formation. A mean of 30.8 min elapsed between needle insertion and ultrasound evaluation. A total of 101 patients who were taking warfarin were studied. They had International Normalized Ratio (INR) values at or above 1.5, and two were found to have small, subclinical hematomas. Of 57 patients taking clopidogrel and/or aspirin, 1 was found to have a small, subclinical hematoma. In the control group (51 patients taking neither class of medication), no hematomas were found on ultrasound. This study suggests that hematoma formation from a standard needle EMG is rare. In addition, hematoma formation in our study group of patients on anticoagulant or antiplatelet medications was also uncommon, and no patients with documented hematomas experienced symptoms. These findings should be considered when determining the feasibility of electrodiagnostic evaluation of patients who are taking anticoagulant or antiplatelet medications.

Original languageEnglish (US)
Pages (from-to)1225-1230
Number of pages6
JournalMuscle and Nerve
Volume38
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Electromyography
Hematoma
Needles
Anticoagulants
Therapeutics
clopidogrel
Muscles
International Normalized Ratio
Platelet Aggregation Inhibitors
Warfarin
Aspirin
Guidelines
Hemorrhage
Control Groups

Keywords

  • Aspirin
  • Clopidogrel
  • Electromyography
  • Hematoma
  • Warfarin

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Physiology (medical)
  • Cellular and Molecular Neuroscience

Cite this

Complications of needle electromyography : Hematoma risk and correlation with anticoagulation and antiplatelet therapy. / Lynch, Stacy L.; Boon, Andrea; Smith, Jay; Harper, Charles M.; Tanaka, Elisa M.

In: Muscle and Nerve, Vol. 38, No. 4, 01.10.2008, p. 1225-1230.

Research output: Contribution to journalArticle

@article{4f09b7869b9541b5b0adc87d1f1d91d4,
title = "Complications of needle electromyography: Hematoma risk and correlation with anticoagulation and antiplatelet therapy",
abstract = "Electromyography (EMG) is considered a relatively safe procedure based primarily on clinical experience. Literature review reveals few reported complications from bleeding or hematoma formation. No evidence-based guidelines exist for EMG procedures in patients who are taking anticoagulant or antiplatelet medications. The purpose of this study was to determine if patients taking anticoagulant or antiplatelet agents exhibit an increased risk of hematoma formation after routine needle EMG of the tibialis anterior muscle when compared to controls. Study subjects underwent routine needle EMG of the tibialis anterior muscle followed by ultrasound examination to evaluate for the presence of hematoma formation. A mean of 30.8 min elapsed between needle insertion and ultrasound evaluation. A total of 101 patients who were taking warfarin were studied. They had International Normalized Ratio (INR) values at or above 1.5, and two were found to have small, subclinical hematomas. Of 57 patients taking clopidogrel and/or aspirin, 1 was found to have a small, subclinical hematoma. In the control group (51 patients taking neither class of medication), no hematomas were found on ultrasound. This study suggests that hematoma formation from a standard needle EMG is rare. In addition, hematoma formation in our study group of patients on anticoagulant or antiplatelet medications was also uncommon, and no patients with documented hematomas experienced symptoms. These findings should be considered when determining the feasibility of electrodiagnostic evaluation of patients who are taking anticoagulant or antiplatelet medications.",
keywords = "Aspirin, Clopidogrel, Electromyography, Hematoma, Warfarin",
author = "Lynch, {Stacy L.} and Andrea Boon and Jay Smith and Harper, {Charles M.} and Tanaka, {Elisa M.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1002/mus.21111",
language = "English (US)",
volume = "38",
pages = "1225--1230",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Complications of needle electromyography

T2 - Hematoma risk and correlation with anticoagulation and antiplatelet therapy

AU - Lynch, Stacy L.

AU - Boon, Andrea

AU - Smith, Jay

AU - Harper, Charles M.

AU - Tanaka, Elisa M.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Electromyography (EMG) is considered a relatively safe procedure based primarily on clinical experience. Literature review reveals few reported complications from bleeding or hematoma formation. No evidence-based guidelines exist for EMG procedures in patients who are taking anticoagulant or antiplatelet medications. The purpose of this study was to determine if patients taking anticoagulant or antiplatelet agents exhibit an increased risk of hematoma formation after routine needle EMG of the tibialis anterior muscle when compared to controls. Study subjects underwent routine needle EMG of the tibialis anterior muscle followed by ultrasound examination to evaluate for the presence of hematoma formation. A mean of 30.8 min elapsed between needle insertion and ultrasound evaluation. A total of 101 patients who were taking warfarin were studied. They had International Normalized Ratio (INR) values at or above 1.5, and two were found to have small, subclinical hematomas. Of 57 patients taking clopidogrel and/or aspirin, 1 was found to have a small, subclinical hematoma. In the control group (51 patients taking neither class of medication), no hematomas were found on ultrasound. This study suggests that hematoma formation from a standard needle EMG is rare. In addition, hematoma formation in our study group of patients on anticoagulant or antiplatelet medications was also uncommon, and no patients with documented hematomas experienced symptoms. These findings should be considered when determining the feasibility of electrodiagnostic evaluation of patients who are taking anticoagulant or antiplatelet medications.

AB - Electromyography (EMG) is considered a relatively safe procedure based primarily on clinical experience. Literature review reveals few reported complications from bleeding or hematoma formation. No evidence-based guidelines exist for EMG procedures in patients who are taking anticoagulant or antiplatelet medications. The purpose of this study was to determine if patients taking anticoagulant or antiplatelet agents exhibit an increased risk of hematoma formation after routine needle EMG of the tibialis anterior muscle when compared to controls. Study subjects underwent routine needle EMG of the tibialis anterior muscle followed by ultrasound examination to evaluate for the presence of hematoma formation. A mean of 30.8 min elapsed between needle insertion and ultrasound evaluation. A total of 101 patients who were taking warfarin were studied. They had International Normalized Ratio (INR) values at or above 1.5, and two were found to have small, subclinical hematomas. Of 57 patients taking clopidogrel and/or aspirin, 1 was found to have a small, subclinical hematoma. In the control group (51 patients taking neither class of medication), no hematomas were found on ultrasound. This study suggests that hematoma formation from a standard needle EMG is rare. In addition, hematoma formation in our study group of patients on anticoagulant or antiplatelet medications was also uncommon, and no patients with documented hematomas experienced symptoms. These findings should be considered when determining the feasibility of electrodiagnostic evaluation of patients who are taking anticoagulant or antiplatelet medications.

KW - Aspirin

KW - Clopidogrel

KW - Electromyography

KW - Hematoma

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=53549087265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549087265&partnerID=8YFLogxK

U2 - 10.1002/mus.21111

DO - 10.1002/mus.21111

M3 - Article

C2 - 18785189

AN - SCOPUS:53549087265

VL - 38

SP - 1225

EP - 1230

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -